SCHEMBL6354804

SCHEMBL6354804

COC(=O)C1CN(c2ccc(C(F)(F)F)cn2)CCN1S(=O)(=O)c1ccc(C)c(CC(=O)O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
HPGD P15428 1/20 0.43
ALDH1A1 P00352 1/20 0.42
KMT2A Q03164 1/20 0.42
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
CA12 O43570 5/20 0.41
CA1 P00915 5/20 0.41
CA2 P00918 5/20 0.41
CA9 Q16790 5/20 0.41
CA4 P22748 4/20 0.41
CA7 P43166 4/20 0.41
TRPV1 Q8NER1 3/20 0.41
F13A1 P00488 1/20 0.41
TGM2 P21980 1/20 0.41
TGM1 P22735 1/20 0.41
KDM4E B2RXH2 4/20 0.41
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5748046 1.00 SMN1; SMN2 (0.43) SMN1; SMN2HPGDALDH1A1KMT2APPARG
SCHEMBL5746828 1.00 SMN1; SMN2 (0.43) SMN1; SMN2HPGDALDH1A1KMT2APPARG
SCHEMBL27754688 0.92 SMN1; SMN2 (0.43) SMN1; SMN2HPGDALDH1A1KMT2APPARG
SCHEMBL27734620 0.92 SMN1; SMN2 (0.43) SMN1; SMN2HPGDALDH1A1KMT2APPARG
SCHEMBL5747494 0.89 CXCR3 (0.47) SMN1; SMN2HPGDKMT2APPARGPPARD
SCHEMBL5749321 0.87 HSD11B1 (0.46) SMN1; SMN2HPGDALDH1A1KMT2APPARG
SCHEMBL5746954 0.86 NR1H2 (0.47) SMN1; SMN2HPGDPPARGPPARDPPARA
SCHEMBL6349119 0.85 GCKR (0.43) ALDH1A1KMT2AF13A1TGM2TGM1
SCHEMBL5797656 0.85 GCKR (0.43) ALDH1A1KMT2AF13A1TGM2TGM1
SCHEMBL5748378 0.85 GCKR (0.43) ALDH1A1KMT2AF13A1TGM2TGM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD SMN1; SMN2 2173/4885HPGD 1108/4885ALDH1A1 883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.